@ClancyNeil @wfwrighID @MSG_ERC@FungalDoc @GermHunterMD @DrLuisO @pranita_tamma We’ve utilized the expanded access program several times. Emailing the above address is the best way to start. They were extremely helpful and expedient to acquire it.
Remember to consider this condition in #transplant patients with persistent viremia unresponsive to treatment or without clearly attributable symptoms/disease! #transplantID Great updated review here by Guy Handley: https://t.co/1hW9VJR9bK
@TheTxIDjournal Review of HHV6 diagnosis and treatment, a review of evidence would be really beneficial as there are many practice variations; @handleyg4 would be great individual to include to write it
Doing a 10,000 Dollars Giveaway.
Crypto has given me a lot.
Time to give back now.
SHARE this and Comment below.
Will distribute 10K between a few people.
Let's Go 🚀🚀
@ErinMcCreary @emilylheil This paragraph alone should be required reading for everyone in the ID space! Most succinct version of “it’s not just bioavailability” that I’ve read! Now we need one for “it’s not just ‘CNS penetration’”…
@IdVilchez@FungalDoc@tmhohl71 @wfwrighID @DrToddLee @Boghuma @boulware_dr@kierenamarr @jobadd @davidvanduin I would definitely be worried about your antifungal and ECMO. Vori, posa, isa all have significant drug sequestration, and Ampho B as well. Higher lipophilicty and protein binding = greater drug sequestration. Given the severity, would favor using higher dosing
.@Lane_Kiffin hopes everyone who comes to games this season gets vaccinated.
“I know it’s controversial to say, but it’s the right thing to do.” https://t.co/pd3jSHsmQF
There you have it in @NEJM.
Pfizer is ~90% effective against delta. AstraZeneca is ~70%. This is similar to effectiveness against other variants, including alpha.
Vaccines work, even against variants.
Get vaccinated if you haven't already.
https://t.co/FV1Rr5fiVa
@transplantID Those two cases completed HD GCV with no UL-97 reemergence! Hindsight, it would have been nice to know the exact codon mutation in each b/c of high-level vs low-level GCV resistance for future management